Assay Detail

CHEMBL5128071

Review assay metadata, readout intent, target linkage, and publication context from the same page.

Binding

Inhibition of PDE5 (unknown origin)

ChEMBL ↗

Free Research Context This assay will appear in recent viewed items on this browser. Open the demo workspace to preview project-only review queues.

Research home Demo workspace

Target

Unchecked (CHEMBL612545) ↗

Open DB target context

Use one target anchor to keep assay intent, target linkage, and tested compound review aligned.

Loading context

Unchecked (CHEMBL612545) is the working anchor for this assay review. Loading the live Open DB target snapshot…

Primary target Unchecked

CHEMBL612545

Anchored from Assay target.

Protein identity Unchecked

Disease frame Disease evidence pending

Open the live target snapshot or evidence card before reviewing assay metadata so target fit and disease framing stay reusable.

Review focus Open DB context pending

Open the live target snapshot before relying on this target frame across surface handoff.

Open target snapshot Open evidence card Search with this context

Total Activities

Compounds Tested

Activity Types

Assay Parameters

Assay Information

Assay Type	Binding
Organism	Homo sapiens
Confidence	0 — Uncurated / Unknown
Curated By	Autocuration

Target

Unchecked (CHEMBL612545) ↗

Type

UNCHECKED

Publication

Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.

Xi M, Sun T, Chai S, Xie M, Chen S, Deng L, Du K, Shen R, Sun H.
Eur J Med Chem (2022) 232 : 114170 -114170
PubMed 35144038 · DOI

Activity Statistics

Type	Count	Avg pChEMBL	Best pChEMBL
IC50	3	8.90	9.12

Compounds Tested

Compound	Name	Phase	Activities	Best pChEMBL
CHEMBL28079	ZAPRINAST	2.0	1	9.12
CHEMBL779	TADALAFIL	4.0	1	8.92
CHEMBL192	SILDENAFIL	4.0	1	8.66

Activity Data

Compound	Name	Type	Rel.	Value	Units	pChEMBL
CHEMBL28079	ZAPRINAST	IC50	=	0.76	nM	9.12
CHEMBL779	TADALAFIL	IC50	=	1.2	nM	8.92
CHEMBL192	SILDENAFIL	IC50	=	2.2	nM	8.66